Medical Information
Afrique
 

This medical information website is intended only for healthcare professionals in Africa. This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

I am a healthcare professional registered to practice in AfricaYes, I am a healthcare professional
SelectI am a healthcare professional registered to practice in AfricaYes, I am a healthcare professional
I am not a Healthcare ProfessionalNo, go back to the patient portal
SelectI am not a Healthcare ProfessionalNo, go back to the patient portal
Where do you work / live?
SubmitSubmit
I am a Healthcare Professional in another country.

Congress Materials

The information on this page pertains to selected congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.

Poster
Cortes JE,  Milojkovic D,  Gambacorti-Passerini C,  García-Gutiérrez V,  Mauro MJ,  Leip E, Purcell S,  Viqueira A,  Brümmendorf TH June 4, 2022 ASCO 2022 Hematology

Bosutinib in Newly Diagnosed Chronic Myeloid Leukemia: Gastrointestinal, Liver, Effusion and Renal Safety Characterization in the BFORE Trial

View Presentation View Abstract Plain Language Summary
Poster
Jakubowiak A, Bahlis NJ, Raje NS, Costello CL, Dholaria B, Solh M, Levy MY, Tomasson MH, Dube H, Damore MA, Jiang S, Basu C, Skoura A, Chan EM, Trudel S, Chu MP, Gasparetto C, Dalovisio A, Sebag M, Lesokhin AM June 4, 2022 ASCO 2022 Hematology

Elranatamab, a BCMA-Targeted T-Cell Redirecting Immunotherapy, for Patients with Relapsed or Refractory Multiple Myeloma: Results from MagnetisMM-1 

View Presentation View Abstract Plain Language Summary
Poster
Grosicki S,  Crafoord J, Koh Y, White D, Mellqvist U-H, Leip E, Kudla A, Finn G, Pruchniewski Ł June 4, 2022 ASCO 2022 Hematology

MagnetisMM-5: An Open-Label, Multicenter, Randomized Phase 3 Study of Elranatamab as Monotherapy and in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma

View Presentation View Abstract Plain Language Summary
Poster
Fonseca R, Kuroda J, Ishida T, Popat R, Huang JSY, Yver A, Vandendries E, Elmeliegy M, Ma WD, Sborov DW June 4, 2022 ASCO 2022 Hematology

MagnetisMM-9: An Open-Label, Multicenter, Non-Randomized Phase 1/2 Study of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma

View Presentation View Abstract Plain Language Summary
Poster
Patel K, Sano D, Maris M, Lesokhin A, von Keudell G, Doucette K, Ramachandren R, Pavlov D,  Uger R, Molloy N, Bruns I, Scheuber A, Iyer S June 4, 2022 ASCO 2022 Hematology

TTI-622-01: A Phase 1a/1b Dose-Escalation and Expansion Trial of TTI-622 in Patients with Advanced Hematologic Malignancies, Including Diffuse Large B Cell Lymphoma (DLBCL)

View Presentation
Poster
Patel K, Orlowski RZ, Doucette K, Maris M, Pianko M, Ramachandren R, Stevens D, Vesole D, Uger R, Scheuber A, Molloy N, Bruns I, Lesokhin A June 4, 2022 ASCO 2022 Hematology

TTI-622-01: A Phase 1a/1b Dose-Escalation and Expansion Trial of TTI-622 in Patients with Advanced Hematologic Malignancies, Including Multiple Myeloma

View Presentation
Oral Presentation
Lesokhin AM, Arnulf B, Nievizky R, Mohty M, Bahlis NJ, Tomasson MH, Rodrίguez-Otero P, Quach H, Raje NS, Iida S, Raab M-S, Czibere A, Sullivan S, Leip E, Viqueira A, Leleu X June 5, 2022 ASCO 2022 Hematology

Initial Safety Results for MagnetisMM-3: A Phase 2 Trial of Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

View Presentation View Abstract Plain Language Summary
Poster
Lesokhin AM, Arnulf B, Niesvizky R, Mohty M, Bahlis NJ, Tomasson MH, Rodrίguez-Otero P, Quach H, Raje NS, Iida S, Raab M-S, Czibere A, Sullivan S, Leip E, Viqueira A, Leleu X June 10, 2022 EHA 2022 Hematology

A Phase 2 Trial of Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma: Initial Safety Results for MagnetisMM-3

View Presentation View Abstract Plain Language Summary
Poster
Montesinos P, Kota V, Brandwein J, Bousset P, Benner RJ, Vandendries E, McMullin MF June 10, 2022 EHA 2022 Hematology

A Phase 4 Study of Fractionated Gemtuzumab Ozogamicin on QT Interval and Safety in Patients With Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia

View Presentation View Abstract Plain Language Summary
Poster
Cortes JE, Milojkovic D, Gambacorti-Passerini C, Garcia-Gutierrez V, Mauro MJ, Leip E, Purcell S, Viqueira A, Brummendorf TH June 10, 2022 EHA 2022 Hematology

Bosutinib in Newly Diagnosed Chronic Myeloid Leukemia: Gastrointestinal, Liver, Effusion and Renal Safety Characterization in the BFORE Trial

View Presentation View Abstract Plain Language Summary